DE69817393D1 - Neue heterozyklische verbindungen - Google Patents

Neue heterozyklische verbindungen

Info

Publication number
DE69817393D1
DE69817393D1 DE69817393T DE69817393T DE69817393D1 DE 69817393 D1 DE69817393 D1 DE 69817393D1 DE 69817393 T DE69817393 T DE 69817393T DE 69817393 T DE69817393 T DE 69817393T DE 69817393 D1 DE69817393 D1 DE 69817393D1
Authority
DE
Germany
Prior art keywords
substituted
group
atom
heterocyclic
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69817393T
Other languages
English (en)
Other versions
DE69817393T2 (de
Inventor
Ayumu Kurimoto
Tetsuhiro Ogino
Hajime Kawakami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Publication of DE69817393D1 publication Critical patent/DE69817393D1/de
Application granted granted Critical
Publication of DE69817393T2 publication Critical patent/DE69817393T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
DE69817393T 1997-11-28 1998-11-26 Neue heterozyklische verbindungen Expired - Lifetime DE69817393T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP34742297 1997-11-28
JP34742297 1997-11-28
JP36745197 1997-12-11
JP36745197 1997-12-11
JP36744997 1997-12-17
JP36744997 1997-12-17
PCT/JP1998/005318 WO1999028321A1 (en) 1997-11-28 1998-11-26 Novel heterocyclic compounds

Publications (2)

Publication Number Publication Date
DE69817393D1 true DE69817393D1 (de) 2003-09-25
DE69817393T2 DE69817393T2 (de) 2004-06-17

Family

ID=27341247

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69817393T Expired - Lifetime DE69817393T2 (de) 1997-11-28 1998-11-26 Neue heterozyklische verbindungen

Country Status (12)

Country Link
US (1) US6329381B1 (de)
EP (1) EP1035123B1 (de)
JP (1) JP4375901B2 (de)
KR (1) KR100613634B1 (de)
AT (1) ATE247654T1 (de)
AU (1) AU732361B2 (de)
CA (1) CA2311742C (de)
DE (1) DE69817393T2 (de)
ES (1) ES2205573T3 (de)
NZ (1) NZ504800A (de)
TW (1) TWI222973B (de)
WO (1) WO1999028321A1 (de)

Families Citing this family (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359078A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0003828D0 (sv) * 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
JP2008531580A (ja) * 2000-12-08 2008-08-14 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾因子の標的化送達のための組成物および方法
SE0101322D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
JP4331944B2 (ja) * 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
WO2003020889A2 (en) * 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
EP1455700A4 (de) * 2001-11-16 2007-02-14 3M Innovative Properties Co Verfahren und zusammensetzungen im zusammenhang mit irm-verbindungen und toll-rezeptor-pfaden
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US7189730B2 (en) 2001-12-18 2007-03-13 Cv Therapeutics, Inc. A2A adenosine receptor antagonists
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
WO2003072026A2 (en) * 2002-02-22 2003-09-04 3M Innovative Properties Company Method of reducing and treating uvb-induced immunosuppression
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
WO2004032829A2 (en) 2002-08-15 2004-04-22 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
GB0221828D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
TWI349671B (en) 2002-09-27 2011-10-01 Dainippon Sumitomo Pharma Co Novel adenine derivative and its use
WO2004053452A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Assays relating to toll-like receptor activity
AU2003287324A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
WO2004060319A2 (en) 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
US7375180B2 (en) * 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
US7485432B2 (en) * 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
JP2006519866A (ja) 2003-03-04 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー Ｕｖ誘発性の表皮の新形成の予防的治療
US7179253B2 (en) 2003-03-13 2007-02-20 3M Innovative Properties Company Method of tattoo removal
ATE556711T1 (de) * 2003-03-13 2012-05-15 3M Innovative Properties Co Verfahren zur verbesserung der hautqualität
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
WO2004108072A2 (en) * 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
JP2007500712A (ja) * 2003-07-31 2007-01-18 スリーエム イノベイティブ プロパティズ カンパニー カプセル化および徐放のための組成物
WO2005016275A2 (en) * 2003-08-05 2005-02-24 3M Innovative Properties Company Formulations containing an immune response modifier
WO2005018551A2 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
WO2005018574A2 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
EP1658035A4 (de) 2003-08-25 2007-08-22 3M Innovative Properties Co Abgabe von die immunantwort modifizierenden verbindungen
CA2536136C (en) 2003-08-27 2012-10-30 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
CA2536578A1 (en) * 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
WO2005025583A2 (en) 2003-09-05 2005-03-24 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
WO2005023190A2 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US20050096259A1 (en) * 2003-10-31 2005-05-05 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
CA2545825A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
EP1685129A4 (de) 2003-11-14 2008-10-22 3M Innovative Properties Co Oximsubstituierte imidazoringverbindungen
MY161812A (en) 2003-11-25 2017-05-15 3M Innovative Properties Co Substituted imidazo ring systems and methods
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
WO2005055932A2 (en) * 2003-12-02 2005-06-23 3M Innovative Properties Company Therapeutic combinations and methods including irm compounds
GB0328243D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Methods
JP4970048B2 (ja) * 2003-12-22 2012-07-04 カトリーケ・ウニフェルジテイト・ルーベン・カー・イュー・ルーベン・アール・アンド・ディ イミダゾ［４，５−ｃ］ピリジン化合物および抗ウイルス治療の方法
JP2007517035A (ja) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
JP2007517044A (ja) 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
TW200612932A (en) 2004-03-24 2006-05-01 3M Innovative Properties Co Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005092893A1 (ja) * 2004-03-26 2005-10-06 Dainippon Sumitomo Pharma Co., Ltd. ９置換−８−オキソアデニン化合物
US20070225303A1 (en) * 2004-03-26 2007-09-27 Haruhisa Ogita 8-Oxoadenine Compound
AU2005231440B9 (en) * 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
JP2007532572A (ja) * 2004-04-09 2007-11-15 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調整剤を送達させるための方法、組成物および調製物
ES2560449T3 (es) 2004-05-28 2016-02-19 Oryxe Una mezcla para administración transdérmica de compuestos de peso molecular bajo y alto
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006023381A1 (en) * 2004-08-16 2006-03-02 Taigen Biotechnology Pyrimidinone compounds
WO2006029223A2 (en) * 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
ES2459368T3 (es) 2004-12-17 2014-05-09 Anadys Pharmaceuticals, Inc. Compuestos de 3H-oxazolo y 3H-tiazolo[4,5-d]pirimidin-2-ona 3,5-disustituidos y 3,5,7-trisustituidos y profármacos de los mismos
WO2006069193A2 (en) * 2004-12-21 2006-06-29 Gilead Sciences, Inc. Imidazo[4,5-c]pyridine compound and method of antiviral treatment
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
US8461174B2 (en) 2004-12-30 2013-06-11 3M Innovative Properties Company Treatment for cutaneous metastases
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
WO2006107853A2 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
EP1863814A1 (de) 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. 1-substitutierte pyrazolo-(3,4-c)-ringverbindungen als cytokinbiosynthese-modulatoren für die behandlung viraler infektionen und neoplastischer erkrankungen
JP2008540396A (ja) 2005-05-04 2008-11-20 ファイザー・リミテッド 癌およびｃ型肝炎などのウイルス感染を治療するためのトール様受容体調節薬としての２−アミド−６−アミノ−８−オキソプリン誘導体
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
TW200801003A (en) * 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
TW200745114A (en) * 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
JPWO2007034881A1 (ja) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
EP1939199A4 (de) 2005-09-22 2010-10-20 Dainippon Sumitomo Pharma Co Neue adeninverbindung
WO2007034916A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
EP1939201A4 (de) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co Neue adeninverbindung
JPWO2007034817A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
ATE474842T1 (de) 2005-11-21 2010-08-15 Anadys Pharmaceuticals Inc Neues verfahren zur herstellung von 5-amino-3h- thiazoloä4,5-düpyrimidin-2-on
JPWO2007060918A1 (ja) 2005-11-24 2009-05-07 大日本住友製薬株式会社 新規なメモリーｃｔｌ誘導増強剤
US8951528B2 (en) * 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
AU2007257423B8 (en) * 2006-05-31 2012-02-16 The Regents Of The University Of California Purine analogs
ATE496924T1 (de) 2006-06-22 2011-02-15 Anadys Pharmaceuticals Inc Prodrugs von 5-amino-3-(3'-deoxy-beta-d- ribofuranosyl)-thiazolä4,5-düpyrimidin-2,7-dion
US8138172B2 (en) * 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
KR101143596B1 (ko) * 2006-07-07 2012-05-11 길리애드 사이언시즈, 인코포레이티드 신규의 피리다진 화합물 및 이의 용도
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
BRPI0714831A2 (pt) 2006-07-18 2013-04-02 Anadys Pharmaceuticals Inc composto, composiÇço farmacÊutica e mÉtodos de modulaÇço de atividades imuno da citoquina em paciente, de tratamento de infecÇço de vÍrus c da hepatite em paciente e de desordem relacionada com proliferaÇço em mamÍfero necessitado do mesmo
TW200831105A (en) 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
PL2125007T3 (pl) 2007-02-07 2014-07-31 Univ California Koniugaty syntetycznych agonistów TLR i ich zastosowania
EP2132209B8 (de) 2007-03-19 2014-04-16 AstraZeneca AB 9-substituierte 8-oxoadeninverbindungen als modulatoren des toll-like-rezeptors (tlr7)
EP2139894B1 (de) 2007-03-19 2011-10-26 AstraZeneca AB 9-substituierte 8-oxoadeninverbindungen als modulatoren des toll-like-receptor (tlr7)
TW200902018A (en) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
JPWO2008114819A1 (ja) * 2007-03-20 2010-07-08 大日本住友製薬株式会社 新規アデニン化合物
PT2155743E (pt) 2007-05-08 2012-10-30 Astrazeneca Ab Imidazoquinolinas com propriedades imunomoduladoras
TWI434849B (zh) * 2007-06-29 2014-04-21 Gilead Sciences Inc 類鐸（Ｔｏｌｌ－ｌｉｋｅ）受體７之調節劑
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
WO2009034386A1 (en) * 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
UY31531A1 (es) 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
WO2009091031A1 (ja) * 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co., Ltd. アデニン化合物の製造方法
US8865896B2 (en) 2008-01-17 2014-10-21 Astrazeneca Aktiebolag Method for preparing adenine compound
US20090202626A1 (en) * 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
PE20120106A1 (es) 2008-12-09 2012-02-20 Gilead Sciences Inc Moduladores de receptores tipo toll
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP2607365A1 (de) 2009-02-11 2013-06-26 The Regents of The University of California Modulatoren des toll-ähnlichen Rezeptors und Behandlung von Krankheiten
JP5685184B2 (ja) * 2009-04-28 2015-03-18 全薬工業株式会社 プリン誘導体およびそれを用いた抗腫瘍剤
GB0908772D0 (en) * 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
BRPI1010937A2 (pt) 2009-05-21 2019-09-24 Astrazeneca Ab composto, uso de um composto, e, método para tratar câncer
JP6282395B2 (ja) 2009-05-27 2018-02-21 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 異なる放出速度の構成要素を有するナノキャリア
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
MX343908B (es) 2009-08-26 2016-11-28 Selecta Biosciences Inc * Composiciones que inducen la ayuda de las células t.
EA020488B1 (ru) 2009-10-22 2014-11-28 Джилид Сайэнс, Инк. Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
JP2013512859A (ja) 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
WO2011079016A1 (en) * 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
CN103221067B (zh) 2010-04-30 2016-01-06 泰勒麦迪克斯公司 磷脂药物类似物
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
NO2575876T3 (de) 2010-05-26 2018-05-05
IT1401281B1 (it) * 2010-08-05 2013-07-18 Univ Firenze Preparazione di coniugati fra derivati dell'adenina e proteine allergeniche e loro uso in immunoterapia specifica per il trattamento delle malattie allergiche.
US20120083473A1 (en) 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators
EP2640190A4 (de) 2010-11-05 2016-05-11 Selecta Biosciences Inc Modifizierte nikotinische verbindungen und zugehörige verfahren
JP5978225B2 (ja) 2010-12-16 2016-08-24 大日本住友製薬株式会社 治療に有用なイミダゾ［４，５−ｃ］キノリン−１−イル誘導体
US8895570B2 (en) 2010-12-17 2014-11-25 Astrazeneca Ab Purine derivatives
TW201247706A (en) * 2011-03-08 2012-12-01 Baylor Res Inst Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
PH12013502033A1 (en) 2011-04-08 2014-01-06 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
AU2012258220B2 (en) 2011-05-18 2017-01-19 Janssen Sciences Ireland Uc Quinazoline derivatives for the treatment of viral infections and further diseases
JP6460789B2 (ja) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
JP6415979B2 (ja) 2011-06-03 2018-10-31 スリーエム イノベイティブ プロパティズ カンパニー ヒドラジノ１ｈ−イミダゾキノリン−４−アミン及びこれから調製された複合体
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
US20130039954A1 (en) 2011-07-29 2013-02-14 Selecta Biosciences, Inc. Control of antibody responses to synthetic nanocarriers
JP6349256B2 (ja) 2011-11-09 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のためのプリン誘導体
DK2812331T3 (en) 2012-02-08 2019-04-08 Janssen Sciences Ireland Unlimited Co PIPERIDINOPYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
KR102194585B1 (ko) 2012-05-18 2020-12-23 다이닛본 스미토모 세이야꾸 가부시끼가이샤 카르복실산 화합물
HRP20161125T1 (hr) 2012-07-13 2016-11-18 Janssen Sciences Ireland Uc Makrociklički purini za liječenje virusnih infekcija
AU2013301450B2 (en) 2012-08-10 2018-01-18 Janssen Sciences Ireland Uc Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
EP2712866A1 (de) 2012-10-01 2014-04-02 Centre National de la Recherche Scientifique (CNRS) 1,2,4-Triazinderivate zur Behandlung von Virusinfektionen
DK2906563T3 (en) 2012-10-10 2018-06-06 Janssen Sciences Ireland Uc PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES
NZ706226A (en) 2012-11-16 2019-09-27 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
CN105025854A (zh) 2013-01-07 2015-11-04 宾夕法尼亚大学董事会 治疗皮肤t细胞淋巴瘤的组合物和方法
CN105189468B (zh) 2013-02-21 2018-10-30 爱尔兰詹森科学公司 用于治疗病毒性感染的2-氨基嘧啶衍生物
CN105188744A (zh) 2013-03-14 2015-12-23 哈佛大学的校长及成员们 基于纳米颗粒的组合物
PL2978429T3 (pl) 2013-03-29 2017-08-31 Janssen Sciences Ireland Uc Deazapurynony makrocykliczne do leczenia infekcji wirusowych
KR102280559B1 (ko) 2013-05-24 2021-07-22 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 추가적인 질환의 치료를 위한 피리돈 유도체
NO3030563T3 (de) 2013-06-27 2018-01-06
AU2014298540B2 (en) 2013-07-30 2018-08-09 Janssen Sciences Ireland Uc Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
EP3556353A3 (de) 2014-02-25 2020-03-18 Merck Sharp & Dohme Corp. Lipidnanopartikel-impfstoffadjuvanzien und antigenfreisetzungssysteme
AU2015279738A1 (en) 2014-06-25 2016-12-22 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
KR20190104438A (ko) 2014-07-11 2019-09-09 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 톨-유사 수용체의 조정제
BR112017002811B1 (pt) 2014-08-15 2022-09-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Compostos de pirrolopirimidina usados como agonista de tlr7 e seu uso, composição farmacêutica e kit
CN106715431A (zh) 2014-09-16 2017-05-24 吉利德科学公司 Toll样受体调节剂的固体形式
CA2969587A1 (en) * 2014-12-05 2016-06-09 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
WO2016164640A1 (en) * 2015-04-09 2016-10-13 Carson Dennis A Synthetic tlr4 and tlr7 ligands to prevent, inhibit or treat liver disease
US11260018B2 (en) 2015-09-17 2022-03-01 Jrx Biotechnology, Inc. Approaches for improving skin hydration and moisturization
WO2017056494A1 (en) 2015-09-29 2017-04-06 Sumitomo Dainippon Pharma Co., Ltd. Adenine conjugate compounds and their use as vaccine adjuvants
US10526309B2 (en) 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors
TWI558709B (zh) * 2015-10-07 2016-11-21 Chia Tai Tianqing Pharmaceutical Group Co Ltd Pyrrolopyrimidine ring compounds, their use and pharmaceutical compositions
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
EP3478688A1 (de) 2016-07-01 2019-05-08 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidine zur behandlung von virusinfektionen
SG11201901633WA (en) * 2016-08-29 2019-03-28 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
EP3519406B1 (de) 2016-09-29 2022-02-23 Janssen Sciences Ireland Unlimited Company Pyrimidin prodrugs zur behandlung von viralen infekten und anderen erkrankungen
ES2906439T3 (es) 2016-12-05 2022-04-18 Apros Therapeutics Inc Compuestos de pirimidina que contienen grupos ácidos
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
US11253476B2 (en) 2017-03-29 2022-02-22 Sumitomo Dainippon Pharma Co., Ltd. Vaccine adjuvant formulation
US10494370B2 (en) * 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
AU2018391899A1 (en) 2017-12-21 2020-07-02 Sumitomo Pharma Co., Ltd. Combination drug including TLR7 agonist
CA3034912A1 (en) 2018-02-28 2019-08-28 Pfizer Inc. Il-15 variants and uses thereof
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
WO2019173289A1 (en) 2018-03-05 2019-09-12 The University Of Chicago Methods and compositions for treating cancer with ecm-affinity peptides linked to cytokines
US11525010B2 (en) 2018-05-23 2022-12-13 Pfizer Inc. Antibodies specific for GUCY2c and uses thereof
BR112020022897A2 (pt) 2018-05-23 2021-02-23 Pfizer Inc. anticorpos específicos para cd3 e usos dos mesmos
TW202003475A (zh) 2018-06-04 2020-01-16 美商亞博創新醫藥有限公司 含酸性基團之嘧啶化合物
TW202011986A (zh) 2018-07-23 2020-04-01 公益財團法人日本健康科學振興財團 包含流感疫苗之組合物
US20210213010A1 (en) * 2018-07-24 2021-07-15 Torque Therapeutics, Inc. Tlr7/8 agonists and liposome compositions
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2020255039A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
US11702474B2 (en) 2019-12-17 2023-07-18 Pfizer Inc. Antibodies specific for CD47, PD-L1, and uses thereof
JP2023533793A (ja) 2020-07-17 2023-08-04 ファイザー・インク 治療用抗体およびそれらの使用
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024105159A1 (en) * 2022-11-16 2024-05-23 University Of Zurich Ligands of the m6a-rna readers
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations
WO2025248505A1 (en) 2024-05-31 2025-12-04 Wayne State University Methods for treating endometrial and ovarian hyperproliferative disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8511222D0 (en) 1985-05-02 1985-06-12 Wellcome Found Antiviral compounds
IL78643A0 (en) 1985-05-02 1986-08-31 Wellcome Found Purine derivatives,their preparation and pharmaceutical compositions containing them
JPH08165292A (ja) * 1993-10-07 1996-06-25 Techno Res Kk アデニン誘導体、その製造法及び用途
ATE283855T1 (de) 1996-07-03 2004-12-15 Sumitomo Pharma Neue purinderivate
IL129319A0 (en) 1996-10-25 2000-02-17 Minnesota Mining & Mfg Immune response modifier compounds for treatment of TH2 mediated and related diseases

Also Published As

Publication number Publication date
US6329381B1 (en) 2001-12-11
WO1999028321A9 (en) 1999-09-10
TWI222973B (en) 2004-11-01
AU1260299A (en) 1999-06-16
EP1035123A4 (de) 2001-12-12
JP4375901B2 (ja) 2009-12-02
CA2311742A1 (en) 1999-06-10
KR20010032571A (ko) 2001-04-25
EP1035123B1 (de) 2003-08-20
AU732361B2 (en) 2001-04-26
KR100613634B1 (ko) 2006-08-18
EP1035123A1 (de) 2000-09-13
CA2311742C (en) 2009-06-16
ATE247654T1 (de) 2003-09-15
DE69817393T2 (de) 2004-06-17
ES2205573T3 (es) 2004-05-01
NZ504800A (en) 2001-10-26
WO1999028321A1 (en) 1999-06-10

Similar Documents

Publication Publication Date Title
DE69817393D1 (de) Neue heterozyklische verbindungen
ATE73815T1 (de) Adenosin-derivate und pharmazeutische zusammenstellungen, welche diese als aktiven bestandteil enthalten.
DK459086A (da) Quinazolinderivater
ATE145906T1 (de) Benzamid-derivate
DK132188D0 (da) Anvendelse af tetrahydrobenz(c,d)indol-6-carboxamider som anxiolytika
DK0420121T3 (da) Antitumormiddel
DE69001722D1 (de) Entzuendungshemmende und/oder antiallergische zusammensetzung, die glutathionderivate enthaelt.
ATE126796T1 (de) Quinazolinderivate und ihre herstellung.
ATE205209T1 (de) Chinolincarbonsäurederivate und ihre salze
DK0420224T3 (da) Anthihepatopatisk middel
FI895139A0 (fi) Pyrrolidinderivat.
DE3762342D1 (de) 1-acylaminomethylimidazo(1,2-a) chinolinderivate, ihre herstellung und therapeutische verwendung.
DE69523819D1 (de) Quinolin-Derivate und diese enthaltende pharmazeutische Zusammensetzungen
DE3884878D1 (de) Uricosuretische Zusammensetzung.
DE3782235D1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur prophylaxe und zur behandlung von herzinsuffizienz.
DE3782229D1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
DE69501810D1 (de) Verwendung von 5-Thia-1,4-Diazabicyclo [4.2.0] Octane-3,8-dioxo Verbindungen in der Antitumor-Therapie

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: DAINIPPON SUMITOMO PHARMA CO., LTD., OSAKA, JP